A Phase 3 study of vadadustat for the treatment of anemia in late-stage CKD patients
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Vadadustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- 20 Jan 2025 New trial record
- 13 Jan 2025 According to a Akebia Therapeutics media release, the company announced that it received feedback from the U.S. Food and Drug Administration (FDA) on its protocol submission for a label expansion study and is incorporating feedback as appropriate and also expects to begin the trial in mid-2025.